Literature DB >> 16846409

Effects of minimal dose aprotinin on blood loss and fibrinolytic system-complement activation in coronary artery bypass grafting surgery.

Ferit Cicekcioglu1, Kerim Cagli, Mustafa Emir, Murat Topbas, Zeki Catav, Erol Sener, Oguz Tasdemir.   

Abstract

BACKGROUND: To determine whether 500,000 KIU aprotinin is effective to reduce blood loss in coronary artery bypass grafting (CABG) and to evaluate the effects of this regimen on hematologic parameters.
METHODS: Forty-four patients scheduled for primary CABG were randomly assigned to the aprotinin (n = 24) or control group (n = 20). In aprotinin group, aprotinin was administered in two equal doses (before skin incision and added to the pump prime). Ventilation time, intensive care unit stay, mediastinal tube drainage, hospitalization, transfusion requirements, and postoperative morbidities and mortality were noted. Hematologic markers of fibrinolytic activity and complement activation were also measured pre- and postoperatively.
RESULTS: Although less mediastinal drainage occurred in aprotinin group, the difference was not statistically significant. Other postoperative variables like transfusion requirements, morbidities, and mortality were also found to be similar between groups. Among hematologic parameters, only postoperative levels of alpha2-antiplasmin and plasminogen activator inhibitor-1 were significantly higher in aprotinin group.
CONCLUSIONS: Although plasmin inhibitors begin to rise at this very low aprotinin dosage, it is not advisable to use this aprotinin regimen in CABG patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16846409     DOI: 10.1111/j.1540-8191.2006.00267.x

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  4 in total

Review 1.  Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.

Authors:  David A Henry; Paul A Carless; Annette J Moxey; Dianne O'Connell; Barrie J Stokes; Dean A Fergusson; Katharine Ker
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

Review 2.  The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis.

Authors:  David Henry; Paul Carless; Dean Fergusson; Andreas Laupacis
Journal:  CMAJ       Date:  2008-12-02       Impact factor: 8.262

3.  Anti-inflammatory effect of aprotinin: a meta-analysis.

Authors:  Jeremiah R Brown; Andrew W J Toler; Robert S Kramer; R Clive Landis
Journal:  J Extra Corpor Technol       Date:  2009-06

Review 4.  Auxiliary activation of the complement system and its importance for the pathophysiology of clinical conditions.

Authors:  Markus Huber-Lang; Kristina N Ekdahl; Rebecca Wiegner; Karin Fromell; Bo Nilsson
Journal:  Semin Immunopathol       Date:  2017-09-12       Impact factor: 9.623

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.